CASI News and Press, CASI Pharmaceuticals Inc. From 03/28/24

CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS PR Newswire BEIJING , March 28, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing a...

2024-03-19 08:19:47 ET More on Fusion Pharmaceuticals Fusion Pharmaceuticals' Partnerships Strengthen Long-Term Outlook Biggest stock movers today: FUSN, NCMI, crypto stocks and more AstraZeneca will buy Fusion Pharmaceuticals for ~$2B Seeking Alpha’s ...

2024-03-08 10:00:23 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Waters, Moderna most shorted ...

2024-03-06 08:24:28 ET More on Pre-market losers & stocks. Datasea jumps 23% as subsidiary enters a potential $30M sale agreement Seeking Alpha’s Quant Rating on BeyondSpring Historical earnings data for BeyondSpring Financial information for Beyon...

2024-03-05 08:46:46 ET CASI Pharmaceuticals ( Nasdaq: CASI ) shares rose 25% at $6.36 after company and BioInvent International AB ( BINV ) announced preliminary encouraging data for BI-1206 in combination with rituximab in patients with relapsed/refractory indolent Non-Hodgki...

2024-03-05 07:49:55 ET DENVER, Colo., Mar 05, 2024 ( 247marketnews.com )- CASI Pharmaceuticals, Inc. (NASDAQ: CASI ) and BioInvent International AB (Nasdaq Stockholm: BINV) announced, this morning, initial efficacy data for BI-1206, a first-in-class fully human monoclonal antibody (...

CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China PR Newswire BEIJING and LUND, Sweden , March 5, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq...

2024-02-25 12:00:00 ET More on AstraZeneca, Bristol-Myers, etc. Eli Lilly: Will It Be The First Ever Trillion-Dollar Drug Company? Eli Lilly: Yes, It Is Too Late To Join The Party Eli Lilly: Very Strong Fundamentals, But Market Is Euphoric Phase 3 data for As...

2024-02-18 02:05:00 ET Summary LianBio plans to stop all its operations by the end of 2024 and will distribute a $4.80 dividend/share ($528M) to its shareholders. Yiviva signed a memorandum of understanding with AstraZeneca China for an R&D collaboration at AstraZeneca’...

CASI PHARMACEUTICALS ANNOUNCES FIRST DOSING OF FOLOTYN® IN CHINA PR Newswire BEIJING , Feb. 16, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company specializing in the development and commercialization of innovative th...